# Vektor Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vektor-medical

- Industry: Software
- Headquarters: San Diego, US
- Website: www.vektormedical.com
- Total disclosed funding: $29M
- Latest round: Series A (Feb 2, 2024)
- Investors on record: 2

## About

Based in California, US, and co-founded by Mike Monko (Executive Chairman) David Krummen, Gordon Ho, and Andrew McCulloch, in 2017, Vektor Medical, Inc. operates as a provider of artificial intelligence (AI) technology for arrhythmia treatment. In February 2024, the firm raised USD 16 million in series A funding co-led by Solas BioVentures and TVM Capital Life Science. The firm as of February 2024, is led by its CEO, Rob Krummen.

The company’s flagship product, vMap addresses the global health crisis of arrhythmia by unlocking valuable insights contained in standard electrocardiograms (ECGs). vMap is an advanced algorithm and AI-based arrhythmia analysis tool designed to improve cardiac ablation outcomes, optimize workflows, and increase procedural efficiency. vMap, rapidly and accurately locate source locations for both focal and fibrillation-type arrhythmias. Vektor’s non-invasive, four-chamber mapping tool provides physicians with intuitive and accurate insights, enabling them to streamline both mapping and ablation procedures.

The company plans to utilize the February 2024 funding to accelerate the development of its management and operation.

## Funding rounds

- Series A, Feb 2, 2024, $29M — TVM Capital Life Science, Solas BioVentures

## Investors

- TVM Capital Life Science (https://capitalatlas.ai/funds/tvm-capital-life-science) — Series A
- Solas BioVentures (https://capitalatlas.ai/funds/solas-bioventures) — Series A